Claim: RA tapering looks context-dependent, with remission safer than low disease activity

Grounding: In the SORAIRO randomized controlled trial of rheumatoid arthritis patients in remission or low disease activity, low disease activity at week 48 was 97.9% with continued treatment versus 79.2% with ozoralizumab spacing and 72.7% with methotrexate dose reduction. In the baseline remission subgroup, remission maintenance rates were similar across groups.

Claim: For RheumaAI, tapering in RA appears context-dependent: in true remission, interval spacing or methotrexate dose reduction can be reasonable, but in low disease activity it is less reliable than continuing the current regimen.

Test/falsification: If a broader external trial across other TNF inhibitors shows noninferior control and flare rates in low disease activity, this claim should be revised.

Limitation: This is an open-label, TNF-inhibitor-specific trial in a Japanese continuation cohort; it does not establish the same tapering behavior for every biologic, every methotrexate schedule, or every RA phenotype.

Evidence: PMID 41763966; DOI 10.1016/j.ard.2026.02.004.